Toward Ultrasound Molecular Imaging With Phase-Change Contrast Agents: An In Vitro Proof of Principle

Paul S. Sheeran, Jason E. Streeter, Lee B. Mullin, Terry O Matsunaga, Paul A. Dayton

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Phase-change contrast agents (PCCAs), which normally consist of nanoscale or microscale droplets of liquid perfluorocarbons in an encapsulating shell, can be triggered to undergo a phase transition to the highly echogenic gaseous state upon the input of sufficient acoustic energy. As a result of the subsequent volumetric expansion, a number of unique applications have emerged that are not possible with traditional ultrasound microbubble contrast agents. Although many studies have explored the therapeutic aspects of the PCCA platform, few have examined the potential of PCCAs for molecular imaging purposes. In this study, we demonstrate a PCCA-based platform for molecular imaging using αvβ3-targeted nanoscale PCCAs composed of low-boiling-point perfluorocarbons. In vitro, nanoscale PCCAs adhered to target cells, could be activated and imaged with a clinical ultrasound system and produced a six-fold increase in image contrast compared with non-targeted control PCCAs and a greater than fifty-fold increase over baseline. Data suggest that low-boiling-point nanoscale PCCAs could enable future ultrasound-based molecular imaging techniques in both the vascular and extravascular spaces.

Original languageEnglish (US)
Pages (from-to)893-902
Number of pages10
JournalUltrasound in Medicine and Biology
Volume39
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Molecular Imaging
Contrast Media
Ultrasonography
Fluorocarbons
boiling
platforms
In Vitro Techniques
Microbubbles
encapsulating
phase control
Phase Transition
image contrast
Acoustics
imaging techniques
microbalances
Blood Vessels
expansion
acoustics

Keywords

  • Acoustic droplet vaporization
  • Contrast agent
  • Molecular imaging
  • Perfluorocarbon droplet
  • Phase-change

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Biophysics

Cite this

Toward Ultrasound Molecular Imaging With Phase-Change Contrast Agents : An In Vitro Proof of Principle. / Sheeran, Paul S.; Streeter, Jason E.; Mullin, Lee B.; Matsunaga, Terry O; Dayton, Paul A.

In: Ultrasound in Medicine and Biology, Vol. 39, No. 5, 05.2013, p. 893-902.

Research output: Contribution to journalArticle

Sheeran, Paul S. ; Streeter, Jason E. ; Mullin, Lee B. ; Matsunaga, Terry O ; Dayton, Paul A. / Toward Ultrasound Molecular Imaging With Phase-Change Contrast Agents : An In Vitro Proof of Principle. In: Ultrasound in Medicine and Biology. 2013 ; Vol. 39, No. 5. pp. 893-902.
@article{0937e0e3785541948b952f29e54864a3,
title = "Toward Ultrasound Molecular Imaging With Phase-Change Contrast Agents: An In Vitro Proof of Principle",
abstract = "Phase-change contrast agents (PCCAs), which normally consist of nanoscale or microscale droplets of liquid perfluorocarbons in an encapsulating shell, can be triggered to undergo a phase transition to the highly echogenic gaseous state upon the input of sufficient acoustic energy. As a result of the subsequent volumetric expansion, a number of unique applications have emerged that are not possible with traditional ultrasound microbubble contrast agents. Although many studies have explored the therapeutic aspects of the PCCA platform, few have examined the potential of PCCAs for molecular imaging purposes. In this study, we demonstrate a PCCA-based platform for molecular imaging using αvβ3-targeted nanoscale PCCAs composed of low-boiling-point perfluorocarbons. In vitro, nanoscale PCCAs adhered to target cells, could be activated and imaged with a clinical ultrasound system and produced a six-fold increase in image contrast compared with non-targeted control PCCAs and a greater than fifty-fold increase over baseline. Data suggest that low-boiling-point nanoscale PCCAs could enable future ultrasound-based molecular imaging techniques in both the vascular and extravascular spaces.",
keywords = "Acoustic droplet vaporization, Contrast agent, Molecular imaging, Perfluorocarbon droplet, Phase-change",
author = "Sheeran, {Paul S.} and Streeter, {Jason E.} and Mullin, {Lee B.} and Matsunaga, {Terry O} and Dayton, {Paul A.}",
year = "2013",
month = "5",
doi = "10.1016/j.ultrasmedbio.2012.11.017",
language = "English (US)",
volume = "39",
pages = "893--902",
journal = "Ultrasound in Medicine and Biology",
issn = "0301-5629",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Toward Ultrasound Molecular Imaging With Phase-Change Contrast Agents

T2 - An In Vitro Proof of Principle

AU - Sheeran, Paul S.

AU - Streeter, Jason E.

AU - Mullin, Lee B.

AU - Matsunaga, Terry O

AU - Dayton, Paul A.

PY - 2013/5

Y1 - 2013/5

N2 - Phase-change contrast agents (PCCAs), which normally consist of nanoscale or microscale droplets of liquid perfluorocarbons in an encapsulating shell, can be triggered to undergo a phase transition to the highly echogenic gaseous state upon the input of sufficient acoustic energy. As a result of the subsequent volumetric expansion, a number of unique applications have emerged that are not possible with traditional ultrasound microbubble contrast agents. Although many studies have explored the therapeutic aspects of the PCCA platform, few have examined the potential of PCCAs for molecular imaging purposes. In this study, we demonstrate a PCCA-based platform for molecular imaging using αvβ3-targeted nanoscale PCCAs composed of low-boiling-point perfluorocarbons. In vitro, nanoscale PCCAs adhered to target cells, could be activated and imaged with a clinical ultrasound system and produced a six-fold increase in image contrast compared with non-targeted control PCCAs and a greater than fifty-fold increase over baseline. Data suggest that low-boiling-point nanoscale PCCAs could enable future ultrasound-based molecular imaging techniques in both the vascular and extravascular spaces.

AB - Phase-change contrast agents (PCCAs), which normally consist of nanoscale or microscale droplets of liquid perfluorocarbons in an encapsulating shell, can be triggered to undergo a phase transition to the highly echogenic gaseous state upon the input of sufficient acoustic energy. As a result of the subsequent volumetric expansion, a number of unique applications have emerged that are not possible with traditional ultrasound microbubble contrast agents. Although many studies have explored the therapeutic aspects of the PCCA platform, few have examined the potential of PCCAs for molecular imaging purposes. In this study, we demonstrate a PCCA-based platform for molecular imaging using αvβ3-targeted nanoscale PCCAs composed of low-boiling-point perfluorocarbons. In vitro, nanoscale PCCAs adhered to target cells, could be activated and imaged with a clinical ultrasound system and produced a six-fold increase in image contrast compared with non-targeted control PCCAs and a greater than fifty-fold increase over baseline. Data suggest that low-boiling-point nanoscale PCCAs could enable future ultrasound-based molecular imaging techniques in both the vascular and extravascular spaces.

KW - Acoustic droplet vaporization

KW - Contrast agent

KW - Molecular imaging

KW - Perfluorocarbon droplet

KW - Phase-change

UR - http://www.scopus.com/inward/record.url?scp=84875812488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875812488&partnerID=8YFLogxK

U2 - 10.1016/j.ultrasmedbio.2012.11.017

DO - 10.1016/j.ultrasmedbio.2012.11.017

M3 - Article

C2 - 23453380

AN - SCOPUS:84875812488

VL - 39

SP - 893

EP - 902

JO - Ultrasound in Medicine and Biology

JF - Ultrasound in Medicine and Biology

SN - 0301-5629

IS - 5

ER -